{"id":"W2139891818","doi":"10.1200/jco.2011.38.0402","title":"Brentuximab Vedotin (SGN-35) in Patients With Relapsed or Refractory Systemic Anaplastic Large-Cell Lymphoma: Results of a Phase II Study","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":990,"is_retracted":false,"has_abstract":true,"ca_institutions":"Seagen (Canada)","funders":"Takeda Oncology","keywords":"Brentuximab vedotin; Medicine; Anaplastic large-cell lymphoma; Internal medicine; Neutropenia; Antibody-drug conjugate; Phases of clinical research; Refractory (planetary science); Oncology; CD30; Adverse effect; Lymphoma; Gastroenterology; Chemotherapy; Immunology; Antibody; Monoclonal antibody","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001427329,0.000716144,0.001107587,0.0001726331,0.0001891342,0.000515204,0.0003303558,0.0005468331,0.000836938],"category_scores_gemma":[0.0007443147,0.0002450716,0.0005913233,0.0002237481,0.0004199214,0.0003468338,0.0001473533,0.0009937803,0.000317303],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0003841491,"about_ca_system_score_gemma":0.0005676245,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0005747862,"about_ca_topic_score_gemma":0.001005954,"domain_scores_codex":[0.99966,0.0001676142,0.00002510164,0.00005528369,0.00004714872,0.00004471881],"domain_scores_gemma":[0.9994911,0.0001088814,0.00009320172,0.00004038354,0.0000350141,0.0002313762],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.3532468,0.05704103,0.1049524,0.001516199,0.003121138,0.001799448,0.001142903,0.005003355,0.1460038,0.0002205196,0.004858246,0.3210942],"study_design_scores_gemma":[0.2763712,0.5452787,0.1594289,0.00009642788,0.00129613,0.002188366,0.0001663924,0.003232045,0.006875992,0.0001344967,0.004885307,0.00004607195],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9967389,0.00207969,0.000190056,0.00009827822,0.0000219261,0.0002482471,0.0001479357,0.0000314108,0.0004434643],"genre_scores_gemma":[0.9967592,0.001220717,0.0005135837,0.0002859266,0.00005578731,0.0001867972,0.0006717365,0.000008085171,0.0002981125],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.001427329,"threshold_uncertainty_score":0.007548511,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.05924066866749524,"score_gpt":0.4100624161401102,"score_spread":0.350821747472615,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}